EXEL Collaborates With MRK for Late-Stage Colorectal Cancer Study

Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Open original source
Exelixis teams up with Merck to advance zanzalintinib in a phase III colorectal cancer study, expanding its pipeline beyond Cabometyx.
Open original source